Meeting Report
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

https://doi.org/10.1038/ki.2015.59Get rights and content
Under an Elsevier user license
open archive

Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals and is the fourth most common cause for renal replacement therapy worldwide. There have been many recent advances in the understanding of its molecular genetics and biology, and in the diagnosis and management of its manifestations. Yet, diagnosis, evaluation, prevention, and treatment vary widely and there are no broadly accepted practice guidelines. Barriers to translation of basic science breakthroughs to clinical care exist, with considerable heterogeneity across countries. The Kidney Disease: Improving Global Outcomes Controversies Conference on ADPKD brought together a panel of multidisciplinary clinical expertise and engaged patients to identify areas of consensus, gaps in knowledge, and research and health-care priorities related to diagnosis; monitoring of kidney disease progression; management of hypertension, renal function decline and complications; end-stage renal disease; extrarenal complications; and practical integrated patient support. These are summarized in this review.

KEYWORDS

ADPKD
diagnosis
end-stage renal disease
management
patient support
polycystic kidney disease

Cited by (0)

ABC declared having served on the Otsuka Steering Committee and received grant support from CRISP, MODIFIER, and SPRINT. OD declared having served on Steering Committee for the TEMPO studies. RTG declared having received consultancy fees from Abbott/Abbvie, Bayer, Ipsen and Otsuka (all paid to employer UMCG); research support from the Dutch Kidney Foundation and Ipsen. TH declared having received honoraria from Otsuka Europe and Otsuka Japan. SH declared having received consultancy fees and speaker honorarium from Otsuka. BLK declared having received consultancy fees from Rockwell and speaker honoraria from Rockpoint and Sanofi; NIH grant for a study on Living Kidney Donors. Y Pei declared having received consultancy fees from Otsuka. RDP declared having received consultancy fees from Otsuka (all paid to employer Tufts Medical Center), Sanofi-Genzyme, and Vertex; research support from Otsuka. Y Pirson declared having received speaker honorarium from Otsuka. RWS declared having received consultancy fees from Otsuka and research support from NIH on slowing progression of ADPKD. VET declared having received grant support from NIH, NIDDK, and Otsuka. TW declared having received consultancy fees from PKD Foundation; research support from Otsuka; royalties from a joint licensing agreement with Athena Laboratories and Johns Hopkins on sales of PKD gene testing. DCW declared having received consultancy fees from Otsuka. KUE, DO, and RT reported no relevant disclosures.

17

Roster is listed in Appendix